GlassScriptPhysician profile
Anna M Torres
NPI 1609237593
$1,907.70
in general payments reported to CMS, 2019-2025
26 companies · $762 in 2025
The $762 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $142 · 2021: $340 · 2022: $158 · 2023: $230 · 2024: $144 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $323.43 | 2019-2025 | |
| Novo Nordisk INC | $294.39 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $267.30 | 2025 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $186.05 | 2019-2022 | |
| Abbvie INC. | $125.76 | 2021-2025 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $68.93 | 2021-2022 | |
| Amgen INC. | $67.48 | 2024-2025 | Krystexxa, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.61 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $58.99 | 2020-2023 | Farxiga |
| Dexcom, INC. | $57.23 | 2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $54.83 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $54.42 | 2020-2025 | Pediarix, Bexsero, Shingrix |
| Teva Pharmaceuticals USA, INC. | $53.67 | 2019-2021 | |
| Edwards Lifesciences Corporation | $35.40 | 2025 | Sapien 3 Ultra Resilia |
| Eisai INC. | $32.60 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $18.31 | 2025 | Aptima |
| Merck Sharp & Dohme LLC | $17.89 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Biohaven Pharmaceuticals, INC. | $16.83 | 2021 | |
| Corcept Therapeutics | $16.46 | 2023 | Korlym |
| Aimmune Therapeutics, INC. | $16.37 | 2025 | Vowst |
| Shire North American Group INC | $15.55 | 2019 | |
| Therapeuticsmd, INC. | $15.21 | 2019 | |
| Exact Sciences Corporation | $14.84 | 2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $13.51 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.55 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.